Tarsus Pharmaceuticals announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests.

Mr. Farrow is a finance and corporate strategy executive with more than two decades of experience leading teams in the life science industry, including several publicly traded commercial biotech companies. Most recently, Mr. Farrow served as Chief Financial Officer at Global Blood Therapeutics, where he was part of the leadership team that secured regulatory approval and successfully commercialized Oxbryta for the treatment of sickle cell disease. Prior to that, he held other CFO roles at ZS Pharma and Hyperion Therapeutics.

“I’m delighted to welcome Jeff to Tarsus and look forward to his leadership as we enter the next stage of growth and transition into a commercial organization,” Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus, said in a company news release. “Jeff’s robust experience in finance, corporate strategy and business development – as well as his proven track record in supporting companies as they evolve into successful commercial enterprises – will help position us to transform into a leading eye care company.”

“I’m excited to join Tarsus at this very important and exciting time in the company’s evolution, where we have the opportunity to create and build an entirely new category in eye care and potentially help millions of patients suffering from Demodex blepharitis,” said Mr. Farrow. “I am enthusiastic about joining this extremely talented and motivated team to help take Tarsus to the next level and deliver value to patients and shareholders.”